These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 998504)

  • 21. Multiple comparison of several antiarrhythmic agents by acute oral drug testing in patients with chronic ventricular arrhythmias.
    Facchini M; Bonazzi O; Priori SG; Varisco T; Zuanetti G; Schwartz PJ
    Eur Heart J; 1988 May; 9(5):462-70. PubMed ID: 3402461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration.
    Chimienti M; Regazzi MB; La Rovere MT; Salerno JA; Previtali M; Montericcio V; Rondanelli R; Montemartini C
    Cardiovasc Drugs Ther; 1988 Dec; 2(5):679-86. PubMed ID: 2484920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of intravenous quinidine.
    Swerdlow CD; Yu JO; Jacobson E; Mann S; Winkle RA; Griffin JC; Ross DL; Mason JW
    Am J Med; 1983 Jul; 75(1):36-42. PubMed ID: 6859083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Encainide for ventricular arrhythmias: placebo-controlled and standard comparison trials.
    Morganroth J
    Am J Cardiol; 1986 Aug; 58(5):74C-82C. PubMed ID: 3092623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinidine for ventricular arrhythmias: value of electrophysiologic testing.
    DiMarco JP; Garan H; Ruskin JN
    Am J Cardiol; 1983 Jan; 51(1):90-5. PubMed ID: 6849270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias.
    Ryan W; Engler R; LeWinter M; Karliner JS
    Am J Cardiol; 1979 Feb; 43(2):285-91. PubMed ID: 760482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of oral quinidine effects on sinus node function in sick sinus syndrome patients.
    Vera Z; Awan NA; Mason DT
    Am Heart J; 1982 Jan; 103(1):80-4. PubMed ID: 7055049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of flecainide with quinidine for suppression of chronic stable ventricular ectopic depolarizations. A double-blind randomized study in ambulatory outpatients.
    Salerno DM; Hodges M; Granrud G; Sharkey P
    Ann Intern Med; 1983 Apr; 98(4):455-60. PubMed ID: 6340575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute oral antiarrhythmic testing with disopyramide.
    García-Barreto D; Toruncha A; Gonzalez-Gomez A; Llerena L; Groning E; Hernandez-Cañero A
    Clin Cardiol; 1981; 4(6):330-5. PubMed ID: 7326884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and electrophysiological effects of intravenous quinidine in man.
    Hirschfeld DS; Ueda CT; Rowland M; Scheinman MM
    Br Heart J; 1977 Mar; 39(3):309-16. PubMed ID: 849392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flecainide versus quinidine: results of a multicenter trial.
    Hodges M; Salerno DM; Granrud G
    Am J Cardiol; 1984 Feb; 53(5):66B-71B. PubMed ID: 6364770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.
    Coumel P; Leclercq JF; Assayag P
    Am J Cardiol; 1984 Nov; 54(9):60D-66D. PubMed ID: 6208770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mexiletine and quinidine in ventricular ectopy.
    Fenster PE; Hanson CD
    Clin Pharmacol Ther; 1983 Aug; 34(2):136-42. PubMed ID: 6347497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine.
    Hohnloser SH; van de Loo A; Baedeker F
    J Am Coll Cardiol; 1995 Oct; 26(4):852-8. PubMed ID: 7560608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of digoxin pharmacokinetics by a single dose of quinidine.
    Chen TS; Friedman HS
    JAMA; 1980 Aug; 244(7):669-72. PubMed ID: 6156244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid elimination of quinidine in pediatric patients.
    Szefler SJ; Pieroni DR; Gingell RL; Shen DD
    Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.
    Bozic B; Uzelac TV; Kezic A; Bajcetic M
    Mini Rev Med Chem; 2018; 18(6):468-475. PubMed ID: 28685701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electropharmacologic testing in sustained ventricular tachycardia associated with coronary heart disease: value of the response to intravenous procainamide in predicting the response to oral procainamide and oral quinidine treatment.
    Oseran DS; Gang ES; Rosenthal ME; Mandel WJ; Peter T
    Am J Cardiol; 1985 Nov; 56(13):883-6. PubMed ID: 3904387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short- and long-term therapeutic efficacy of quinidine sulfate for the treatment of chronic ventricular arrhythmias.
    Panidis I; Morganroth J
    J Clin Pharmacol; 1982; 22(8-9):379-84. PubMed ID: 6752212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.